Study of homocysteine and its correlation with biochemical parameters in patients with chronic renal failure

Riyam Shaker

doi:10.53730/ijhs.v6nS4.10541

Authors

Riyam Shaker
riyam.sajet@nust.edu.iq
National University for Science and Technology

Keywords:

chronic renal failure, homocysteine, vitamin B12 , folic acid

Abstract

Homocysteine is an amino acid produced when proteins are broken down. A high homocysteine level, also called hyperhomocysteinemia, can contribute to arterial damage and blood clots in your blood vessels. Hyperhomocysteinemia (Hhcy) occurs in chronic kidney disease (CKD) patients because of impaired renal metabolism and reduced renal excretion Chronic renal failure is a condition involving a decrease in the kidneys' ability to filter waste and fluid from the blood. It is chronic, meaning that the condition develops over a long period of time and is not reversible. The condition is also commonly known as chronic kidney disease (CKD). The aim of the study is to measure homocysteine levels for patients with chronic renal failure before dialysis and to find the relationship between homocysteine and biochemical parameters such as B12, folic acid, ferritin and albumin. Study Design: Blood samples were obtained from (130) men and women. It was divided into (68) hemodialysis patients, aged from (20-80) years and (62) control, aged from (20-80) years, and they were campared.

Downloads

Download data is not yet available.

References

A. Anurag, “A Study on the Levels of Folic Acid, Vitamin B12 and Plasma Homocysteine in Patients with Chronic Kidney Disease.,” J. Assoc. Physicians India, vol. 70, no. 4, pp. 11–12, 2022.

A. J. Abutaha, “Homocysteine and hematological indices in hemodialysis patients at Al-Shifa hospital, Gaza Strip,” 2013.

A. J. W. Branten, D. W. Swinkels, I. S. Klasen, and J. F. M. Wetzels, “Serum ferritin levels are increased in patients with glomerular diseases and proteinuria,” Nephrol. Dial. Transplant., vol. 19, no. 11, pp. 2754–2760, 2004.

A. Kooshki, M. Eftekhari Yazdi, M. Yousefi Moghaddam, and R. A. Akbarzadeh, “Status of antioxidant and homocysteine-lowering vitamins related to cardiovascular diseases in hemodialysis patients,” Electron. Physician, vol. 9, no. 7, pp. 4895–4898, 2017, doi: 10.19082/4895.

A. Moustapha et al., “Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis,” Kidney Int., vol. 55, no. 4, pp. 1470–1475, 1999, doi: 10.1046/j.1523-1755.1999.00378.x.

B. L. Zaric, M. Obradovic, V. Bajic, M. A. Haidara, M. Jovanovic, and E. R. Isenovic, “Homocysteine and hyperhomocysteinaemia,” Curr. Med. Chem., vol. 26, no. 16, pp. 2948–2961, 2019.

B. M. Martella et al., “Hcy and the kidney HHcy is present in individuals with declining kidney function, so that this alteration can be considered a major factor in the progression of kidney diseases, mainly CKD(17). Hcy is known to undergo transsulphuration in the kidney. Ther,” J. Bras. Patol. e Med. Lab., vol. 54, pp. 170–176, 2018.

C. H. Jones, H. Akbani, D. C. Croft, and D. P. Worth, “hydration status in hemodialysis pTdatientshe relationship between serum albumin an,” J. Ren. Nutr., vol. 12, no. 4, pp. 209–212, 2002.

C. M. Clase, V. Ki, and R. M. Holden, “Water‐soluble vitamins in people with low glomerular filtration rate or on dialysis: A review,” in Seminars in dialysis, 2013, vol. 26, no. 5, pp. 546–567.

C. van Guldener, “Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?,” Nephrol. Dial. Transplant., vol. 21, no. 5, pp. 1161–1166, 2006.

C. van Guldener, F. Stam, and C. D. A. Stehouwer, “Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation,” Clin. Chem. Lab. Med., vol. 43, no. 10, pp. 1026–1031, 2005.

G. A. Kaysen, G. M. Chertow, R. Adhikarla, B. Young, C. Ronco, and N. W. Levin, “Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients,” Kidney Int., vol. 60, no. 1, pp. 333–340, 2001, doi: 10.1046/j.1523-1755.2001.00804.x.

H. K. Amin, M.-I. K. El-Sayed, and O. F. Leheta, “Homocysteine as a predictive biomarker in early diagnosis of renal failure susceptibility and prognostic diagnosis for end stages renal disease,” Ren. Fail., vol. 38, no. 8, pp. 1267–1275, 2016.

I. Capelli et al., “Folic acid and vitamin B12 administration in CKD, why not?,” Nutrients, vol. 11, no. 2, 2019, doi: 10.3390/nu11020383.

I. Margalit, E. Cohen, E. Goldberg, and I. Krause, “Vitamin B12 Deficiency and the Role of Gender : A Cross-Sectional Study of a Large Cohort,” no. March, 2018, doi: 10.1159/000488326.

K. Kalantar-Zadeh, K. Kalantar-Zadeh, and G. H. Lee, “The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?,” Clin. J. Am. Soc. Nephrol., vol. 1 Suppl 1, pp. 9–18, 2006, doi: 10.2215/CJN.01390406.

M. BOITAN et al., “RELATION BETWEEN HOMOCYSTEINE LEVEL AND MACROANGIOPATHY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.,” Acta Medica Transilv., vol. 24, no. 1, 2019.

M. Ehsani, M. E. Zeynali, M. Abtahi, and A. A. Harati, “linked immunosorbent assay system. The patients were followed up for 1 year to determine the effect of anemia and hyperhomocysteinemia on survival and risk factors of mortality. Normal values for laboratory parameters were considered according to the Kidn,” vol. 18, no. 1, pp. 37–47, 2009.

M. K. Van Gelder, A. C. Abrahams, J. A. Joles, G. A. Kaysen, and K. G. F. Gerritsen, “Albumin handling in different hemodialysis modalities,” Nephrol. Dial. Transplant., vol. 33, no. 6, pp. 906–913, 2018, doi: 10.1093/ndt/gfx191.

M. Katko et al., “Relationship between serum nickel and homocysteine concentration in hemodialysis patients,” Biol. Trace Elem. Res., vol. 124, no. 3, pp. 195–205, 2008, doi: 10.1007/s12011-008-8139-2.

M. M. Sirdah, M. M. Yassin, S. El Shekhi, and A. M. Lubbad, “Homocysteine and vitamin B 12 status and iron deficiency anemia in female university students from Gaza Strip, Palestine,” Rev. Bras. Hematol. Hemoter., vol. 36, pp. 208–212, 2014.

M. Soohoo et al., “Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients,” Nephrol. Dial. Transplant., vol. 32, no. 6, pp. 1024–1032, 2017, doi: 10.1093/ndt/gfw090.

P. L. Spada et al., “Ferritin iron content in haemodialysis patients: Comparison with septic and hemochromatosis patients,” Clin. Biochem., vol. 41, no. 12, pp. 997–1001, 2008, doi: 10.1016/j.clinbiochem.2008.05.003.

R. B. Jain and A. Ducatman, “Perfluoroalkyl acids serum concentrations and their relationship to biomarkers of renal failure: Serum and urine albumin, creatinine, and albumin creatinine ratios across the spectrum of glomerular function among US adults,” Environ. Res., vol. 174, pp. 143–151, 2019.

S. V. Shevchuk et al., “The relationship between homocysteine level and vitamins B12, B9 and B6 status in patients with chronic kidney disease,” Wiad. Lek., vol. 72, no. 4, pp. 532–538, 2019, doi: 10.36740/wlek201904105.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

U. Schwab et al., “Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans,” J. Nutr., vol. 136, no. 1, pp. 34–38, 2006.

V. D. Alvares Delfino, A. C. de Andrade Vianna, A. J. Mocelin, D. S. Barbosa, R. A. Mise, and T. Matsuo, “Hoffer LJ. Testing the homocysteine hypothesis in end-stage renal disease: problems and possible solutions. Kidney Int 2006;69:1507–10,” Nutrition, vol. 23, no. 3, pp. 242–247, 2007, doi: 10.1016/j.nut.2007.01.002.

W. F. Keane et al., “Reviews and Original Articles,” Perit. Dial. Int. J. Int. Soc. Perit. Dial., vol. 16, no. 6, pp. 557–573, 1996, doi: 10.1177/089686089601600606.

Y. E. C. Taes et al., “Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.,” Kidney Int., vol. 66, no. 6, pp. 2422–2428, 2004, doi: 10.1111/j.1523-1755.2004.66019.x.

Y. W. Chiu, J. M. Chang, S. J. Hwang, J. C. Tsai, and H. C. Chen, “Pharmacological dose of vitamin B12 Is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients,” Ren. Fail., vol. 31, no. 4, pp. 278–283, 2009, doi: 10.1080/08860220902780010.